Search
sabizabulin (Veru-111)
Indications:
- investigational agent for treatment of severe Covid-19
Dosage:
- 9 mg PO QD
Clinical significance:
- 55% reduction in deaths vs placebo in hospitalized patients with moderate- severe Covid-19*
* both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL-6 receptor antibodies, & JAK inhibitors
Mechanism of action:
- disrupts microtubules
General
antiviral agent
Database Correlations
PUBCHEM correlations
References
- Ingram I
Whopping Mortality Benefit in Severe COVID Trial.
Oral sabizabulin showed 55% reduction in risk for death in hospitalized patients.
MedPage Today July 7, 2022
https://www.medpagetoday.com/infectiousdisease/covid19/99610
- Barnette KG, Gordon MS, Rodriguez D
Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19:
Interim Analysis.
NEJM Evidence. 2022. July 6.
PMID: 38319812 DOI: 10.1056/EVIDoa2200145
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200145
- Veru
Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized
Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring
Committee Halts Study Early for Overwhelming Efficacy.
https://verupharma.com/news/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55-in-hospitalized-patients-in-interim-analysis-of-phase-3-study-independent-data-monitoring-committee-halts-study-early-for-overwhelmin/